Vancouver, BC, April 06, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) (“Deep Sea Minerals” or the “Company”), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, is pleased to announce the appointment of John Vonglis as a Strategic Advisor to the Company. John is an experienced government, military, defense, and business professional, having served leadership tenures across a variety of public and private sector offices. He serves also as Chairman of the Strategic Advisory Board and Executive Director of Global Government Affairs for NANO Nuclear Energy Inc., where he advises on growth, governance, and strategy at both the domestic and international levels. John has also held similar senior...

NEWPORT BEACH, Calif., April 06, 2026 (GLOBE NEWSWIRE) — NorthStrive Defense Tech LLC (“NorthStrive Defense Tech”), a wholly-owned subsidiary of PMGC Holdings Inc. (the “Company”) (NASDAQ: ELAB), today announced it has acquired rights to a novel drone technology through an exclusive option agreement (“Option Agreement”) with a corporation. The Option Agreement provides NorthStrive Defense Tech with an exclusive option, within the aerospace and defense technologies field (“Field”), to get an exclusive license as to certain patent rights for U.S. Patent No. 12,291,334, covering a next-generation drone system designed to transport payloads across air and water environments. The option (“Option”) is also for a non-exclusive license in the aerospace and defense technologies field as to certain know-how connected to these patent rights,...

David Bibby, President & CEO of Hypercharge, scheduled to speak at Canada’s largest electrification event VANCOUVER, British Columbia, April 06, 2026 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) (the “Company” or “Hypercharge”), a leading, smart electric vehicle (EV) charging solutions provider and network operator, is pleased to announce its gold sponsorship of the EV & Charging Expo 2026, taking place April 8-9, 2026, at the Enercare Centre in Toronto, ON. This marks Hypercharge’s third consecutive year supporting the event as a sponsor, exhibitor, and main stage panel participant. Hypercharge will attend and exhibit at the event, which brings together business and government leaders and organizations advancing transportation electrification. Hypercharge’s booth will also include a dedicated...

SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that a poster presentation and an oral presentation featuring analysis from the Phase 2b FASCINATE 2 trial of denifanstat in MASH will be delivered at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium being held April 12-15, 2026 in Vancouver, BC, Canada. MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium presentation details:Poster Title: Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trialPresenter: Wen-Wei Tsai, Ph.D.,...

— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —  RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Building on the commercial success of ORLADEYO® and the recent acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution in its strategy to build value through development and commercialization of rare disease therapies. Dr. Menon joins BioCryst from Alnylam Pharmaceuticals, where he served as Chief Development Officer, overseeing global clinical development and safety across a broad portfolio spanning multiple therapeutic areas. Under his leadership,...

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, Ontario, April 06, 2026 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (TSX: MHC.U) (TSX:MHC.UN) (“Flagship” or the “REIT”) today announced that senior management will host a conference call on Tuesday, May 5, 2026 at 8:30 a.m. ET to discuss the REIT’s first quarter 2026 results. First Quarter 2026 Results Conference Call and WebcastDATE: Tuesday, May 5, 2026TIME: 8:30 a.m. ETINSTANT JOIN BY PHONE: Conference Call Registration (Click the URL to join the conference call by phone)Please register at least 10 minutes before the start of the call. Upon registration, an email will be sent, including dial-in details and a unique conference call access code required to join the live call.LIVE WEBCAST:Q1 2026...

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m. ET to report its first quarter 2026 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections to Transform Rare Diseases™At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build...

– Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment – – Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year – – Current cash of approximately $100 million now extends cash runway into 2029, through expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies, potential approvals, and the prospect to receive priority review vouchers – – Three-month topline results from full Cohort 1 of Phase 1/2 trial with OPGx-BEST1 remain on track for mid-2026 – RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics”, “Opus”, or the “Company”),...